Dynamics of TNF, IFNG and IL6 gene expression in chronic myeloid leukaemia patients on Imatinib treatment

BESTACH, YESICA; FERRI, CRISTIAN; LARRIPA, IRENE; BELLI, CAROLINA

Miami

Conferencia; 20th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; 2018

European Society of Haematology

Imatinib remains as the preferred tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) patients. Besides its direct action targeting BCR-ABL1, TKI therapy may also influence the anti-tumour response. A limiting anti-CML immune response has been described at diagnosis, while on TKI treatment, the immune system seems to re-activate. Previous studies were designed by different approaches, criteria for timing or the response evaluated were heterogeneous, and longitudinally studies are scare or missing. Our aim was to describe the dynamic of TNF, IFNG and IL6 gene expression regarding molecular response to Imatinib, since there are no previous articles focused on addressing this issue on the same sample used to monitor %BCR-ABL1.This study included 161 peripheral blood samples from 92 CML patients who were analysed according to the molecular response at each time point. In accordance with a basal immune suppression, the expression of TNF, IFNG and IL6 was significantly diminished at diagnosis when compared with healthy controls (N=26) (p=0.0336, p